期刊
CANCER LETTERS
卷 380, 期 1, 页码 87-97出版社
ELSEVIER IRELAND LTD
DOI: 10.1016/j.canlet.2016.06.014
关键词
Nafamostat mesilate; Colorectal cancer; Chemoresistance; Nuclear factor kappa B; Oxaliplatin
类别
资金
- National High Technology Research and Development Program of China (863 Program), China [2015AA020103]
- National Natural Science Foundation of China [81372570, 81572392]
- Natural Science Foundation of Guangdong Province [2014A030312015]
- Science and Technology Program of Guangzhou [15570006, 158100066]
- China Postdoctoral Science Foundation [2015M570746]
Nafamostat mesilate is an anti-inflammatory drug that is usually used to treat pancreatitis. Recent studies show that it can suppress pancreatic cancer via inhibition of the nuclear factor kappa B (NF-kappa B) pathway. However, whether it has anti-tumor activity in some other cancer, including colorectal cancer (CRC), has not been investigated and remained unclear. Here, our study showed that nafamostat mesilate abrogated the constitutive NF-kappa B activation in CRC cells, which is mediated through inhibition of phosphorylation of I kappa B alpha and nuclear translocation of p65. Also, we found that nafamostat mesilate inhibited phosphorylation of Erk in CRC cells. Consistently, our study demonstrated that nafamostat mesilate inhibited the CRC cell proliferation, invasion and migration and induced mitochondria-dependent apoptosis. Furthermore, nafamostat mesilate could reverse oxaliplatin induced NF-kappa B and Erk activation in CRC cells, and enhance the sensitivity of CRC cells to oxaliplatin. Nafamostat mesilate combined with oxaliplatin repressed subcutaneous tumor growth and hepatic metastasis in vivo. Overall, our data suggest that nafamostat mesilate, a relatively non-toxic drug that targets NF-kappa B and Erk, may, in combination with oxaliplatin, represent a novel therapeutic strategy for CRC treatment. (C) 2016 Elsevier Ireland Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据